Tempero Bio
Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. Our lead therapeutic drug candidate, TMP-301, is a potent, orally available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) that is being investigated for the treatment of Substance Use Disorders, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD). Additional discovery is also underway on the potential of TMP-301 to treat other addictive disorders, such as Methamphetamine Use Disorder (MUD) and Polysubstance Use Disorder (PUD).
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
8
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Tempero Bio
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
- PJ
Paul Johnson
&, · Other
EmailPhone - KL
Kevin Li
VP Operations and Program Management · Operations
EmailPhone
Showing 2 of 4 verified contacts
Top roles at Tempero Bio
2 distinct titles indexed · top 2 shown.
- 1&,
- 1vp operations and program management
Sign up to unlock all 4 contacts at Tempero Bio
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Tempero Bio
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.